Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial respiratory enzymes are a diverse group of membrane-bound proteins that constitute the electron transport chain (ETC) and oxidative phosphorylation machinery in bacteria (Cook et al., 2014, J Biol Chem). These enzymes, including NADH dehydrogenases, succinate dehydrogenases, cytochrome complexes, and ATP synthases, work coordinately to generate a proton motive force across the cytoplasmic membrane, which is then used to drive the synthesis of ATP (Bald et al., 2017, Nat Commun). Because bacterial respiratory pathways often differ significantly from their eukaryotic mitochondrial counterparts—utilizing alternative electron donors and acceptors—they represent attractive targets for narrow-spectrum and multi-drug resistant (MDR) antimicrobial therapy (Hards et al., 2018, Front Microbiol). Drugs targeting these enzymes, such as bedaquiline for Mycobacterium tuberculosis, act by disrupting energy metabolism, leading to bacterial stasis or death (Andries et al., 2005, Science). Telacebec (Q203) is another example, targeting the cytochrome bcc complex to inhibit respiration in mycobacteria (Pethe et al., 2013, Nat Med). Other compounds like clofazimine and phenothiazines target the type II NADH dehydrogenase (NDH-2), an enzyme absent in the human mitochondrial respiratory chain (Yano et al., 2011, J Biol Chem). However, the high degree of diversity among bacterial species and the potential for compensatory respiratory pathways present challenges in drug development and the emergence of resistance (Cook et al., 2017, Microbiol Spectr). Safety concerns often involve potential cross-reactivity with human mitochondrial enzymes or off-target effects like QT prolongation (Belardinelli et al., 2013, PLoS ONE). Despite these challenges, the bioenergetic machinery remains a cornerstone for developing next-generation antibiotics against persistent pathogens.
Inhibition of ATP synthase, inhibition of the cytochrome bcc complex (QcrB), and inhibition of NADH dehydrogenase (NDH-2) to disrupt the proton motive force and ATP production (Andries et al., 2005; Pethe et al., 2013; Yano et al., 2011).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial respiratory enzymes.